Drug Profile
AMF 26
Alternative Names: 2-methylcoprophilinamide; AMF-26; M-COPALatest Information Update: 27 Sep 2023
Price :
$50
*
At a glance
- Originator Eisai Co Ltd
- Class Antineoplastics; Pyridines; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists; Proto-oncogene protein c-met inhibitors; Type-2 fibroblast growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 27 Sep 2023 Discontinued - Preclinical for Cancer in Japan (PO)
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in Japan (PO)
- 15 Feb 2017 Chemical structure information added